ADC Landscape
Bicycle Therapeutics
Nectin-4 · Urothelial cancer
Phase 2Antibody–Drug Conjugates
Target
Nectin-4
Payload
MMAE
Payload class
Auristatin
Linker
Cleavable (bicyclic peptide)
Indication
Urothelial cancer
Phase
Phase 2
Overview
Not an antibody — a synthetic bicyclic peptide ('Bicycle') carrying the payload. Smaller, faster tumor penetration and renal clearance: a structurally different bet on the same Nectin-4 target as Padcev.
Technology
Bicycle Therapeutics works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.